The Global Biotech Investment Landscape:

Insights from the US NIH & FDA, and Implications for Hong Kong’s Prospects

Abstract

The biotech industry is undergoing rapid transformation, driven by scientific breakthroughs, regulatory shifts, and evolving investment trends. At the same time, it faces a challenging investment “winter,” marked by tighter funding, increased scrutiny, and market volatility. Amid these shifts, Hong Kong is emerging as a key global biotech hub. Positioned at the crossroads of China’s rapidly expanding biotech ecosystem and strong international partnerships—particularly with the U.S. and the European Union—Hong Kong is uniquely placed to drive the future of biomedical innovation.

With over 20 years of experience overseeing NIH funding and clinical trials, deep regulatory expertise from working with the FDA, and insights as a venture capital partner at a leading Shanghai-based fund, Dr. Bao offers a unique perspective on the global biotech investment landscape. This presentation will examine China’s latest biotech advancements, the U.S. NIH’s critical role in funding biomedical innovation, and the intricacies of the grant application process. By analyzing these key factors, Dr. Bao will provide valuable insights into emerging opportunities and strategic pathways for advancing biotech investment and development in Hong Kong.